Komori
Results2183Linical Co.,Ltd.Information and Communications, Services and Others

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

Revenue for the interim period fell 23.0% year on year to ¥3,739 million, while the operating loss widened from ¥511 million in the same period of the previous year to ¥1,280 million. Although the full-year earnings forecast was left unchanged, order backlog increased from ¥11,673 million at the end of the fiscal year ended March 2026 to ¥15,780 million.

Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
-23
% (year-on-year change in revenue)
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales3,739¥ millionYear on year -23.0%Progress 35.0%
Operating profit-1,280¥ million
Ordinary income-1,360¥ million
Net income attributable to owners of the parent-1,223¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share-¥54.18
Financial position at period-end
Total assets10,427¥ million
of which net assets 2,577 ¥ millionEquity ratio 24.7%vs. prior year-end -8.4pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-1,033,884
Investment+3,248
Financials-427,937
Net change-1,458,573

Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period3,772,952 Thousand yen
Regional sales
Japan1,455,42338.9%
United States840,62922.5%
Europe876,96023.4%
Asia566,89215.2%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,680 million (YoY +23.2%)
Operating profit¥256 million
Ordinary income¥250 million
Net income¥180 million
Revision to Earnings ForecastNo
Annual Dividend Forecast8 Yen → 8 Yen(0.0%)
Factors Behind Changes in Business Performance

Operating deficits continued in key regions, and an operating loss was recorded due to delays in signing large contracts and other factors. The ordinary loss was due to foreign exchange losses and other factors. Meanwhile, order backlog increased as funding shifted to areas including cancer, central nervous system diseases and autoimmune diseases, improving the order environment.

Disclosure regarding the going concern assumption

There is a description of significant events and other matters related to the going concern assumption. However, based on the expected recognition of revenue and collection of cash from contracted order backlog, as well as its cash and deposits on hand, the company determined that no material uncertainty related to the going concern assumption exists. There are no applicable matters to disclose in the notes regarding the going concern assumption.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not disclosed
Depreciation and amortization63,196 Thousand yen
Orders received and order backlogOrder backlog End of fiscal year ended March 2026 ¥11,673 million / End of the interim period for the fiscal year ending March 2027 ¥14,199 million / As of 16 November 2026 ¥15,780 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts, scheduled for 4 December 2026)
Issued Shares at Period-End24,740,000 Shares
Treasury Shares at Period-End2,153,569 Shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 September 2026
Net Sales¥3,739 million (YoY -23.0%)
Operating profit¥-1,280 million
Ordinary income¥-1,360 million
Profit attributable to owners of the parent¥-1,223 million
Net income per share-¥54.18
Equity ratioEnd of the current fiscal period 24.7 / End of previous period 33.1
Total assets¥10,427 million
Net assets¥2,577 million
Cash flows from operating activities-1,033,884 Thousand yen
Cash flows from investing activities3,248 Thousand yen
Cash flows from financing activities-427,937 Thousand yen
Cash and cash equivalents at end of period3,772,952 Thousand yen
Full-year earnings forecastNet Sales ¥10,680 million (YoY +23.2%) / Operating profit ¥256 million / Ordinary income ¥250 million / Net income ¥180 million
Revision to Earnings ForecastNo
Annual Dividend Forecast8 Yen → 8 Yen(0.0%)
Regional salesJapan 1,455,423 Thousand yen / United States 840,629 Thousand yen / Europe 876,960 Thousand yen / Asia 566,892 Thousand yen
Orders received and order backlogOrder backlog End of fiscal year ended March 2026 ¥11,673 million / End of the interim period for the fiscal year ending March 2027 ¥14,199 million / As of 16 November 2026 ¥15,780 million
Depreciation and amortization63,196 Thousand yen
Disclosure regarding the going concern assumptionThere is a description of significant events and other matters related to the going concern assumption. However, based on the expected recognition of revenue and collection of cash from contracted order backlog, as well as its cash and deposits on hand, the company determined that no material uncertainty related to the going concern assumption exists. There are no applicable matters to disclose in the notes regarding the going concern assumption.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not disclosed
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts, scheduled for 4 December 2026)
Issued Shares at Period-End24,740,000 Shares
Treasury Shares at Period-End2,153,569 Shares
Factors Behind Changes in Business PerformanceOperating deficits continued in key regions, and an operating loss was recorded due to delays in signing large contracts and other factors. The ordinary loss was due to foreign exchange losses and other factors. Meanwhile, order backlog increased as funding shifted to areas including cancer, central nervous system diseases and autoimmune diseases, improving the order environment.
Items this document does not state (8)
Operating MarginPayout ratioShareholder Return PolicySegment revenueSegment profitImpairment lossBreakdown of extraordinary income (loss)Material subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company cited continuing operating deficits in its key regions and the recording of an operating loss in the interim period due to delays in signing large contracts and other factors. It attributed the ordinary loss to foreign exchange losses and other factors. Meanwhile, it said the order environment had improved as funding shifted to other disease areas with the winding down of vaccine and therapeutic drug development.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | Linical Co.,Ltd. (2183) timely disclosure | Komori